BAY2927088 is currently being investigated in a randomised phase III trial in first-line HER2 MUT (TKD mutations) NSCLC patients that compared BAY2927088 vs. SoC (cisplatin/carboplatin + pemetrexed + pembrolizumab), and the primary endpoint is PFS, as measured by a blinded independent central review (BICR) (SOHO-02, NCT06452277). The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.